Biomarkers for the effects of benzodiazepines in healthy volunteers

British Journal of Clinical Pharmacology

Volumn 55, Issue 1, 2003, Pages 39-50

  De Visser, S J ^a   Van Der Post, J P ^a   De Waal, P P ^a   Cornet, F ^a   Cohen, A F ^a   Van Gerven, J M A ^a  

^a CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

Author keywords

Benzodiazepines; Biomarker; Cognition; Phase I; Saccadic eye movement

Indexed keywords

ABECARNIL; ADIMAZOLAM; ALPIDEM; ALPRAZOLAM; BENZODIAZEPINE DERIVATIVE; BIOLOGICAL MARKER; BRETAZANIL; BROMAZEPAM; CAMAZEPAM; CLOBAZAM; DIAZEPAM; FLUNITRAZEPAM; FLUTOPRAZEPAM; LORAZEPAM; MEDAZEPAM; MIDAZOLAM; OXAZEPAM; PREMAZEPAM; QUAZEPAM; TEMAZEPAM; UNCLASSIFIED DRUG;

ARTICLE; DOSE RESPONSE; DRUG EFFECT; HUMAN; MEDLINE; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; VISUAL ANALOG SCALE;

BENZODIAZEPINES; BIOLOGICAL MARKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROENCEPHALOGRAPHY; EYE MOVEMENTS; HUMANS; MOTOR SKILLS;

EID: 0037238673     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2002.t01-10-01714.x     Document Type: Article

References (71)

1. de Visser SJ, Post v.d. J, Pieters MSM, Cohen AF, van Gerven JMA. Biomarkers for the effects of antipsychotic drugs in healthy volunteers. Br J Clin Pharmacol 2001;51: 119-132.
2. Spreen O, Strauss E.A Compendium of Neuropsychological Tests; Administration, Norms, and Commentary, 2nd edn. (ISBN 0-19-510019-0) 1998, New York: Oxford University Press, Inc.
3. van Steveninck AL, Schoemaker HC, den Hartigh J, et al. Effects of intravenous temazepam. I. Saccadic eye movements and electroencephalogram after fast and slow infusion to pseudo steady state. Clin Pharmacol Ther 1994;55: 535-545.
4. van Steveninck AL, Verver S, Schoemaker HC, et al. Effects of temazepam on saccadic eye movements: concentration-effect relationships in individual volunteers. Clin Pharmacol Ther 1992;52: 402-408.
5. van Steveninck AL, Schoemaker HC, Pieters MS, Kroon R, Breimer DD, Cohen AF. A comparison of the sensitivities of adaptive tracking, eye movement analysis and visual analog lines to the effects of incremental doses of temazepam in healthy volunteers. Clin Pharmacol Ther 1991;50: 172-180.
6. Bodfish JW, Powell SB, Golden RN, Lewis MH. Blink rate as an index of dopamine function in adults with mental retardation and repetitive behavior disorders. Am J Ment Retard 1995;99: 335-344.
7. Goldberg TE, Maltz A, Bow JN, Karson CN, Leleszi JP. Blink rate abnormalities in autistic and mentally retarded children: relationship to dopaminergic activity. J Am Acad Child Adolesc Psych 1987;26: 336-338.
8. Karson CN. Spontaneous eye-blink rates and dopaminergic systems. Brain 1983;106: 643-653.
9. Richelson E, Nelson A, Neeper R. Binding of benzodiazepines and some major metabolites at their sites in normal human frontal cortex in vitro. J Pharmacol Exp Ther 1991;256: 897-901.
10. Ito K, Asakura A, Yamada Y, Nakamura K, Sawada Y, Iga T. Prediction of the therapeutic dose for benzodiazepine anxiolytics based on receptor occupancy theory. Biopharm Drug Dispos 1997;18: 293-303.
11. Cutson TM, Gray SL, Hughes MA, Carson SW, Hanlon JT. Effect of a single dose of diazepam on balance measures in older people. J Am Geriatr Soc 1997;45: 435-440.
12. File SE, Fluck E, Joyce EM. Conditions under which lorazepam can facilitate retrieval. J Clin Psychopharmacol 1999;19: 349-353.
13. Sambrooks JE, MacCulloch MJ, Rooney JF. The automated assessment of the effect of flurazepam and nitrazepam on mood state. Acta Psychiatr Scand 1975;51: 201-209.
14. Ingum J, Bjorklund R, Volden R, Morland J. Development of acute tolerance after oral doses of diazepam and flunitrazepam. Psychopharmacology (Berl) 1994;113: 304-310.
15. Schachinger H, Muller BU, Strobel W, Langewitz W, Ritz R. Midazolam effects on prepulse inhibition of the acoustic blink reflex. Br J Clin Pharmacol 1999;47: 421-426.
16. Satzger W, Engel RR, Ferguson E, Kapfhammer H, Eich FX, Hippius H. Effects of single doses of alpidem, lorazepam, and placebo on memory and attention in healthy young and elderly volunteers. Pharmacopsychiatry 1990;23(Suppl 3): 114-119.
17. Nielsen-Kudsk F, Jensen TS, Magnussen I, et al. Pharmacokinetics and bioavailability of intravenous and intramuscular lorazepam with an adjunct test of the inattention effect in humans. Acta Pharmacol Toxicol (Copenh) 1983;52: 121-127.
18. Tallone G, Ghirardi P, Bianchi MC, Ravaccia F, Bruni G, Loreti P. Reaction time to acoustic or visual stimuli after administration of camazepam and diazepam in man. Arzneimittelforschung 1980;30: 1021-1024.
19. Unrug A, Coenen A, van Luijtelaar G. Effects of the tranquillizer diazepam and the stimulant methylphenidate on alertness and memory. Neuropsychobiology 1997; 36: 42-48.
20. Kroboth PD, Folan MM, Lush RM, et al. Coadministration of nefazodone and benzodiazepines. I. Pharmacodynamic assessment. J Clin Psychopharmacol 1995;15: 306-319.
21. Kozena L, Frantik E, Horvath M. Vigilance impairment after a single dose of benzodiazepines. Psychopharmacology (Berl) 1995;119: 39-45.
22. Unrug A, van Luijtelaar EL, Coles MG, Coenen AM. Event-related potentials in a passive and active auditory condition: effects of diazepam and buspirone on slow wave positivity. Biol Psychol 1997;46: 101-111.
23. Duka T, Schutt B, Krause W, Dorow R, McDonald S, Fichte K. Human studies on abecarnil a new beta-carboline anxiolytic: safety, tolerability and preliminary pharmacological profile. Br J Clin Pharmacol 1993;35: 386-394.
24. Christensen P, Lolk A, Gram LF, Kragh-Sorensen P. Benzodiazepine-induced sedation and cortisol suppression. A placebo-controlled comparison of oxazepam and nitrazepam in healthy male volunteers. Psychopharmacology (Berl) 1992;106: 511-516.
25. Schaffler K, Klausnitzer W. Single dose study on buspirone versus diazepam in volunteers. Monitoring psychomotor performance via oculomotor, choice reaction and electromyographic parameters. Arzneimittelforschung 1988;38: 282-287.
26. Kelly TH, Foltin RW, Serpick E, Fischman MW. Behavioral effects of alprazolam in humans. Behav Pharmacol 1997;8: 47-57.
27. Abduljawad KA, Langley RW, Bradshaw CM, Szabadi E. Effects of clonidine and diazepam on the acoustic startle response and on its inhibition by 'prepulses' in man. J Psychopharmacol 1997;11: 29-34.
28. Yasui N, Otani K, Kaneko S, et al. A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in alprazolam metabolism. Clin Pharmacol Ther 1996;59: 514-519.
29. Risby ED, Hsiao JK, Golden RN, Potter WZ. Intravenous alprazolam challenge in normal subjects. Biochemical, cardiovascular, and behavioral effects. Psychopharmacology (Berl) 1989;99: 508-514.
30. Ghoneim MM, Mewaldt SP, Hinrichs JV. Dose-response analysis of the behavioral effects of diazepam. II. Psychomotor performance, cognition and mood. Psychopharmacology (Berl) 1984;82: 296-300.
31. Inanaga K, Tanaka M, Mizuki Y. Prediction of clinical efficacy of zopiclone by utilizing two psychophysiological tools in healthy volunteers. Int Pharmacopsych 1982;17(Suppl 2): 109-115.
32. Noderer J, Duka T, Dorow R. [Benzodiazepine antagonism by RO 15-1788: psychometric, hormonal and biophysical parameters]. Anaesthetist 1988;37: 535-542.
33. Golombok S, Lader M. The psychopharmacological effects of premazepam, diazepam and placebo in healthy human subjects. Br J Clin Pharmacol 1984;18: 127-133.
34. O'Neill WM, Hanks GW, White L, Simpson P, Wesnes K. The cognitive and psychomotor effects of opioid analgesics. I. A randomized controlled trial of single doses of dextropropoxyphene, lorazepam and placebo in healthy subjects. Eur J Clin Pharmacol 1995;48: 447-453.
35. Schaffler K, Klausnitzer W. Placebo-controlled study on acute and subchronic effects of buspirone vs bromazepam utilizing psychomotor and cognitive assessments in healthy volunteers. Pharmacopsychiatry 1989;22: 26-33.
36. Healey M, Pickens R, Meisch R, McKenna T. Effects of clorazepate, diazepam, lorazepam, and placebo on human memory. J Clin Psych 1983;44: 436-439.
37. Stacher G, Bauer P, Brunner H, Grunberger J. Gastric acid secretion, serum-gastrin levels and psychomotor function under the influence of placebo, insulin-hypoglycemia, and/or bromazepam. Int J Clin Pharmacol Biopharm 1976;13: 1-10.
38. Palmieri MG, Iani C, Scalise A, et al. The effect of benzodiazepines and flumazenil on motor cortical excitability in the human brain. Brain Res 1999;815: 192-199.
39. van Steveninck AL, Wallnofer AE, Schoemaker RC et al. A study of the effects of long-term use on individual sensitivity to temazepam and lorazepam in a clinical population. Br J Clin Pharmacol 1997;44: 267-275.
40. Wingerson DK, Cowley DS, Kramer GL, Petty F, Roy-Byrne PP. Effect of benzodiazepines on plasma levels of homovanillic acid in anxious patients and control subjects. Psych Res 1996;65: 53-59.
41. Linnoila M, Stapleton JM, Lister Ret al. Effects of single doses of alprazolam and diazepam, alone and in combination with ethanol, on psychomotor and cognitive performance and on autonomic nervous system reactivity in healthy volunteers. Eur J Clin Pharmacol 1990;39: 21-28.
42. Blom MW, Bartel PR, de Sommers K, Van der Meyden CH, Becker PJ. The effects of alprazolam, quazepam and diazepam on saccadic eye movements, parameters of psychomotor function and the EEG. Fundam Clin Pharmacol 1990;4: 653-661.
43. Ochs HR, Greenblatt DJ, Luttkenhorst M, Verburg-Ochs B. Single and multiple dose kinetics of clobazam, and clinical effects during multiple dosage. Eur J Clin Pharmacol 1984;26: 499-503.
44. Hobi V, Dubach UC, Skreta M, Forgo J, Riggenbach H. The effect of bromazepam on psychomotor activity and subjective mood. J Int Med Res 1981;9: 89-97.
45. Giersch A, Lorenceau J. Effects of a benzodiazepine, lorazepam, on motion integration and segmentation: an effect on the processing of line-ends? Vision Res 1999;39: 2017-2025.
46. Green JF, King DJ. The effects of chlorpromazine and lorazepam on abnormal antisaccade and no-saccade distractibility. Biol Psych 1998;44: 709-715.
47. Samara EE, Granneman RG, Witt GF, Cavanaugh JH. Effect of valproate on the pharmacokinetics and pharmacodynamics of lorazepam. J Clin Pharmacol 1997;37: 442-450.
48. Stewart SH, Rioux GF, Connolly JF, Dunphy SC, Teehan MD. Effects of oxazepam and lorazepam on implicit and explicit memory: evidence for possible influences of time course. Psychopharmacology (Berl) 1996;128: 139-149.
49. Vidailhet P, Kazes M, Danion JM, Kauffmann-Muller F, Grange D. Effects of lorazepam and diazepam on conscious and automatic memory processes. Psychopharmacology (Berl) 1996;127: 63-72.
50. Suzuki M, Uchiumi M, Murasaki M. A comparative study of the psychological effects of DN-2327, a partial benzodiazepine agonist, and alprazolam. Psychopharmacology (Berl) 1995;121: 442-450.
51. Fafrowicz M, Unrug A, Marek T, van Luijtelaar G, Noworol C, Coenen A. Effects of diazepam and buspirone on reaction time of saccadic eye movements. Neuropsychobiology 1995;32: 156-160.
52. Suttle AB, Songer SS, Dukes GE, et al. Ranitidine does not alter adinazolam pharmacokinetics or pharmacodynamics. J Clin Psychopharmacol 1992;12: 282-287.
53. Moser L, Macciocchi A, Plum H, Buckmann. Effect of flutoprazepam on skills essential for driving motor vehicles. Arzneimittelforschung 1990;40: 533-535.
54. Nikaido AM, Ellinwood EHJ, Heatherly DG, Gupta SK. Age-related increase in CNS sensitivity to benzodiazepines as assessed by task difficulty. Psychopharmacology (Berl) 1990;100: 90-97.
55. Currie D, Lewis RV, McDevitt DG, Nicholson AN, Wright NA. Central effects of beta-adrenoceptor antagonists. I-Performance and subjective assessments of mood. Br J Clin Pharmacol 1988;26: 121-128.
56. Herbert M, Standen PJ, Short AH, Birmingham AT. A comparison of some psychological and physiological effects exerted by zetidoline (DL308) and by oxazepam. Psychopharmacology (Berl) 1983;81: 335-339.
57. Bittencourt PR, Wade P, Smith AT, Richens A. Benzodiazepines impair smooth pursuit eye movements. Br J Clin Pharmacol 1983;15: 259-262.
58. Hobi V, Kielholz P, Dubach UC. [The effect of bromazepam on fitness to drive (author's transl)]. MMW Munch Med Wochenschr 1981;123: 1585-1588.
59. Ogle CW, Turner P, Markomihelakis H. The effects of high doses of oxprenolol and of propranolol on pursuit rotor performance, reaction time and critical flicker frequency. Psychopharmacologia 1976;46: 295-299.
60. Kaplan GB, Greenblatt DJ, Ehrenberg BL, Goddard JE, Harmatz JS, Shader RI. Differences in pharmacodynamics but not pharmacokinetics between subjects with panic disorder and healthy subjects after treatment with a single dose of alprazolam. J Clin Psychopharmacol 2000;20: 338-346.
61. Blin O, Jacquet A, Callamand S, et al. Pharmacokinetic-pharmacodynamic analysis of mnesic effects of lorazepam in healthy volunteers. Br J Clin Pharmacol 1999;48: 510-512.
62. Hassan PC, Sproule BA, Naranjo CA, Herrmann N. Dose-response evaluation of the interaction between sertraline and alprazolam in vivo. J Clin Psychopharmacol 2000;20: 150-158.
63. Green JF, King DJ, Trimble KM. Antisaccade and smooth pursuit eye movements in healthy subjects receiving sertraline and lorazepam. J Psychopharmacol 2000;14: 30-36.
64. O'Neill WM, Hanks GW, Simpson P, Fallon MT, Jenkins E, Wesnes K. The cognitive and psychomotor effects of morphine in healthy subjects: a randomized controlled trial of repeated (four) oral doses of dextropropoxyphene, morphine, lorazepam and placebo. Pain 2000;85: 209-215.
65. van Steveninck AL, Gieschke R, Schoemaker HC, et al. Pharmacodynamic interactions of diazepam and intravenous alcohol at pseudo steady state. Psychopharmacology (Berl) 1993; 110: 471-478.
66. van Steveninck AL, Gieschke R, Schoemaker RC, et al. Pharmacokinetic and pharmacodynamic interactions of bretazenil and diazepam with alcohol. Br J Clin Pharmacol 1996;41: 565-573.
67. Aranko K, Mattila MJ, Seppala T. Development of tolerance and cross-tolerance to the psychomotor actions of lorazepam and diazepam in man. Br J Clin Pharmacol 1983;15: 545-552.
68. Norris H. The action of sedatives on brain stem oculomotor systems in man. Neuropharmacology 1971;10: 181-191.
69. Bond A, Lader M. Self-concepts in anxiety states. Br J Med Psychol 1976;49: 275-279.
70. Visser S, Jd Gerven JM, Av Schoemaker HC, Cohen AF. Concentration-effect relationships of two infusion rates of the imidazoline antihypertensive agent rilmenidine for blood pressure and development of side-effects in healthy subjects. Br J Clin Pharmacol 2001;51: 423-428.
71. Lehman Brothers. The Fruits of Genomics, 2001. Lehman Brothers Equity Research, 2001.